ORX Stock Overview
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr17.00 |
| 52 Week High | kr20.10 |
| 52 Week Low | kr8.44 |
| Beta | 0.58 |
| 1 Month Change | 15.49% |
| 3 Month Change | 17.57% |
| 1 Year Change | 30.37% |
| 3 Year Change | -62.56% |
| 5 Year Change | -76.12% |
| Change since IPO | -81.11% |
Recent News & Updates
Recent updates
Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03
We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?
May 04Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now
Apr 06Orexo (STO:ORX) Share Prices Have Dropped 22% In The Last Five Years
Mar 16Nikolaj Sørensen Is The President & CEO of Orexo AB (publ) (STO:ORX) And They Just Picked Up 2.1% More Shares
Feb 17Orexo AB (publ) (STO:ORX) Just Reported And Analysts Have Been Cutting Their Estimates
Jan 31
Shareholder Returns
| ORX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -2.9% | -2.3% | 1.8% |
| 1Y | 30.4% | 60.0% | 10.7% |
Return vs Industry: ORX underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: ORX exceeded the Swedish Market which returned 10.7% over the past year.
Price Volatility
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ORX has not had significant price volatility in the past 3 months.
Volatility Over Time: ORX's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 116 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORX fundamental statistics | |
|---|---|
| Market cap | kr585.64m |
| Earnings (TTM) | -kr128.30m |
| Revenue (TTM) | kr638.80m |
0.9x
P/S Ratio-4.6x
P/E RatioIs ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORX income statement (TTM) | |
|---|---|
| Revenue | kr638.80m |
| Cost of Revenue | kr88.90m |
| Gross Profit | kr549.90m |
| Other Expenses | kr678.20m |
| Earnings | -kr128.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -3.72 |
| Gross Margin | 86.08% |
| Net Profit Margin | -20.08% |
| Debt/Equity Ratio | 761.3% |
How did ORX perform over the long term?
See historical performance and comparison